|
Our Company
Management Team
John Reid, Managing Director, is a co-founder and
seed investor in the Company. John has
successfully concentrated in the vital start-up activities of initial funding
and venture capital procurement, information dissemination, and liaison with
legal, financial, medical and scientific advisors in Ireland. Having succeeded in procuring important
licence and technology agreements a key role now is the shaping and
implementation of a comprehensive business development plan, an important
aspect of which will be the identification and selection of a suitably
qualified and experienced CEO.
John has an MSc International Business
Management from Trinity College, Dublin.
Dr. Paul F. Reid,
Chief Scientific Officer, is a co-founder and seed investor in the Company.
Paul is a leading world expert in the therapeutic use of snake venom
neurotoxins. His collaborations with
Prof. Zheng Hong Qin, Harvard University, have led to three new patent
applications on behalf of the Company in relation to proprietary compounds and
publication of a number of articles in peer reviewed international
publications. Paul is widely
experienced in USA medical regulatory affairs and FDA protocols and has been CEO
of several early-stage biotechnology companies in Florida. Paul has extensive experience in drug
production, new drug development, clinical trial design, and experimental
design.
Paul has a Phd
Neuro-biochemistry from Imperial College, London, and BA Microbiology from
Trinity College, Dublin.
Stephen Long is Financial Officer. Stephen has
significant experience at management level in Strategic Planning and
Implementation. His experience ranges from consultancy for young Irish
Companies penetrating foreign markets to Regulatory Compliance for established
Multinationals. Stephen has operated at
Director, Financial Controller and Finance Manager level in various heavily
regulated industries and is recently appointed company secretary to Celtic
Biotech.
Stephen is a Fellow Chartered Certified Accountant and
also holds an MSc in International Business Management.
Scientific Board of Advisors
In addition to Dr. Reid, the Company has assembled a Scientific Board of Advisors retaining the consultative services and contributions of:
Dr. Roscoe Moore, DVM, former Assistant United States Surgeon General and Rear Admiral USPHS (Ret). Dr Moore has focused over his career on the prevention, treatment and control of infectious diseases worldwide. He directed the Epidemiology program for the Howard University Comprehensive Cancer Center and held an oncology faculty appointment in its Medical College. Dr. Moore was also for an extended time the Senior Epidemiologist in the Office of the Director, National Institute for Occupational Health and Safety/CDC having a primary focus on "occupational exposures" and cancer outcomes. Dr Moore is Assistant Professor of Oncology at Howard U. Medical College and a member of the advisory board of directors for the Fogarty International Center/NIH.
Prof. Zheng Hong Qin, Harvard and Suzhou Universities. Prof. Qin is a co-inventor on Celtic Biotech's first patent application and has conducted extensive pre-clinical research on behalf of the Company. His expert knowledge of venom neurotoxins has been a major asset to the Company and has been responsible for Celtic Biotech's peer reviewed published papers to date.
Prof. John Crown, Senior Oncologist, St Vincent’s University Hospital, Dublin, and newly elected Senator, participated significantly in the development of the CB24 Phase Ib clinical trial protocol developed by the company. He is an international renowned Clinical Investigator and a founding member and ex-President of the All Ireland Clinical Oncology Research Group (ICORG).
Dr. Dorothy Bray, Ph.D., CEO of Immunoclin Ltd. Dr. Bray is former head of HIV drug development for Glaxo Smithkline and is a specialist in clinical drug development and the coordination and conduct of clinical trials. She is a France/UK based CRO specialising in bespoke trials of novel and innovative drug therapies.
Dr. Larry Raymond, Chief Science Officer of Receptopharm Inc., Florida. Dr. Raymond specialises in immunology and is an expert in the production of monoclonal antibodies and assay development. He has extensive experience in the development of medicinal therapies from snake venom neurotoxins.
for more information
|